Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Morena

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Blood Advances|December 15, 2022
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AMLVincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, et al.
Lancet (London, England)|June 13, 2016
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trialMaria Sessa, Laura Lorioli, Francesca Fumagalli, et al.
Lancet (London, England)|January 23, 2022
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessFrancesca Fumagalli, Valeria Calbi, Maria Grazia Natali Sora, et al.
The New England Journal of Medicine|April 23, 2025
Long-Term Effects of Atidarsagene Autotemcel for Metachromatic LeukodystrophyFrancesca Fumagalli, Valeria Calbi, Vera Gallo, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Blood Advances|December 15, 2022
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AMLVincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, et al.
Lancet (London, England)|June 13, 2016
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trialMaria Sessa, Laura Lorioli, Francesca Fumagalli, et al.
Lancet (London, England)|January 23, 2022
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessFrancesca Fumagalli, Valeria Calbi, Maria Grazia Natali Sora, et al.
The New England Journal of Medicine|April 23, 2025
Long-Term Effects of Atidarsagene Autotemcel for Metachromatic LeukodystrophyFrancesca Fumagalli, Valeria Calbi, Vera Gallo, et al.
Pageof 6